公开(公告)号：US20230000951A1

公开(公告)日：2023-01-05

申请号：US17834062

申请日：2022-06-07

申请人： Zealand Pharma A/S

发明人： Bjarne DUE LARSEN ,  Jonathan GRIFFIN ,  Lise GIEHM ,  Alistair Vincent Gordon EDWARDS

IPC分类号： A61K38/26 ,  C07K14/605 ,  A61P3/04 ,  A61P3/10

摘要： A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.

公开(公告)号：US20220296471A1

公开(公告)日：2022-09-22

申请号：US17633379

申请日：2020-08-05

申请人： ZEALAND PHARMA A/S

发明人： Christopher GREGORY ,  Michael BARENBOYM

IPC分类号： A61J1/20 ,  A61J1/14

摘要： An adapter (650) for transferring fluid between a first device (100) and a second device (800). The adapter comprises a first end (652) for receiving the first device, wherein the first end includes a side wall for locating around the first device (100). The adapter (650) further comprises a second end (654) for engaging the first device (100), and including a retaining member (656; 658; 662), wherein the retaining member (656; 658; 662) is operable to prevent removal of the first device (100) from the adapter (650) upon engagement of the first device (100) with the second end (654). The first end (652) and the second end (654) are open on both ends to comprise a through-bore extending through the adapter (650). In some cases, the first device (100) may be a drug pen containing insulin.

公开(公告)号：US11286281B2

公开(公告)日：2022-03-29

申请号：US16611518

申请日：2018-05-10

申请人： Zealand Pharma A/S

发明人： Manuel Perez Vazquez ,  M. Monzur Morshed ,  Adam Paul Kafal ,  Jennifer L. Hickey ,  Andrew Roughton

IPC分类号： A61P37/06 ,  A61P29/00 ,  C07K7/56 ,  A61K38/00 ,  C07K7/64

摘要： There is described herein antagonists of α4β7 integrin, and more particularly cyclic peptide antagonists, such as compounds of formula (I).

公开(公告)号：US20210283053A1

公开(公告)日：2021-09-16

申请号：US17203126

申请日：2021-03-16

申请人： Zealand Pharma A/S

发明人： Jesper Skodborg VILLADSEN ,  Tine Elisabeth Gottschalk BØVING

IPC分类号： A61K9/08 ,  A61K38/26 ,  A61K47/18 ,  A61K47/20 ,  A61K47/22 ,  A61K47/02 ,  A61K9/00 ,  A61P3/08

摘要： The present invention relates to formulations of glucagon analogues, or a pharmaceutically acceptable salt thereof and/or a derivative thereof; and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable aqueous liquid formulations of glucagon analogues comprising combinations of excipients that make them suitable for long term storage as liquids, and are capable of use in single-dose (SD) or multi-dose (MD) formulations.

公开(公告)号：US11111273B2

公开(公告)日：2021-09-07

申请号：US16348103

申请日：2017-11-10

申请人： Zealand Pharma A/S

发明人： Mohammed Monzur Morshed ,  Sai Kumar Chakka ,  Jennifer L. Hickey ,  Manuel Perez Vazquez ,  Andrew Roughton ,  Adam Paul Kafal ,  Narendrakumar B. Patel

IPC分类号： C07K7/52 ,  A61P37/06 ,  A61P29/00 ,  C07K5/12 ,  A61K38/00

摘要： There is described herein, multimers comprising a plurality of compounds covalently linked together, the compounds independently being of formula (I).

公开(公告)号：US20210244798A9

公开(公告)日：2021-08-12

申请号：US16841104

申请日：2020-04-06

申请人： Zealand Pharma A/S

发明人： Bjarne DUE LARSEN ,  Jonathan GRIFFIN ,  Lise GIEHM ,  Alistair Vincent Gordon EDWARDS

IPC分类号： A61K38/26 ,  C07K14/605 ,  A61P3/04 ,  A61P3/10

摘要： A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.

公开(公告)号：US10766939B2

公开(公告)日：2020-09-08

申请号：US15074526

申请日：2016-03-18

申请人： Zealand Pharma A/S

发明人： Rasmus Just ,  Oliver Demmer ,  Lise Giehm ,  Jesper Sloth Villadsen ,  Henrik Munch ,  Jesper Mosolff Mathiesen ,  Jolanta Skarbaliene ,  Maria Deryabina ,  Dieter Wolfgang Hamprecht

IPC分类号： C07K14/575 ,  C07K14/47 ,  A61K38/00

摘要： The present invention relates to amylin analogs and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogs have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.

公开(公告)号：US20190338009A1

公开(公告)日：2019-11-07

申请号：US16466930

申请日：2017-12-11

申请人： Zealand Pharma A/S

发明人： Bjarne Due LARSEN ,  Lise GIEHM ,  Alistair Vincent Gordon EDWARDS

IPC分类号： C07K14/605 ,  A61P3/10 ,  A61P1/00

摘要： The invention relates to compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors. The compounds find use, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.

公开(公告)号：US10336802B2

公开(公告)日：2019-07-02

申请号：US15566338

申请日：2016-04-15

申请人： Zealand Pharma A/S ,  Boehringer Ingelheim International GmbH

发明人： Ditte Riber ,  Jakob Lind Tolborg ,  Dieter Wolfgang Hamprecht ,  Leo Thomas

IPC分类号： A61K31/64 ,  A61K38/22 ,  A61K38/26 ,  A61K38/28 ,  A61K45/06 ,  A61K31/135 ,  A61K31/137 ,  A61K31/155 ,  A61K31/365 ,  C07K14/605 ,  A61K31/7048

摘要： The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

公开(公告)号：US20190135886A1

公开(公告)日：2019-05-09

申请号：US16121745

申请日：2018-09-05

申请人： Zealand Pharma A/S

发明人： Rasmus JUST ,  Ditte RIBER ,  Anne Pernille Tofteng SHELTON ,  Torben ØSTERLUND ,  Kate HANSEN ,  Lene JESSEN

IPC分类号： C07K14/575 ,  C07K14/605

摘要： The present invention relates to truncated GIP analogues which comprise one or more substitutions as compared to wild-type GIP and which may have the property of an altered, preferably increased GLP-1 activity, e.g. as assessed in in vitro efficacy assays. The invention provides GIP-GLP-1 dual agonist compounds and associated methods.